Hiroki Tsuboi

  • Citations Per Year
Learn More
Received November 29, 2012; revised manuscript received February 6, 2013; accepted March 11, 2013; released online April 17, 2013 Time for primary review: 26 days Center of Cardiology, Inuyama Chuo Hospital, Inuyama, Japan The current case was presented orally at the following meeting: 139th Japanese Circulation Society Tokai Session, held on July 7, 2012,(More)
INTRODUCTION We compared the effects of morning administration of insulin glulisine + insulin glargine 300 U/mL (G + G300) with that of insulin lispro + insulin glargine biosimilar (L + GB). MATERIALS AND METHODS A total of 30 patients with type 2 diabetes who wore a continuous glucose monitoring device on admission after glucose levels were stabilized by(More)
To investigate whether sodium glucose co-transporter 2 inhibitors (SGLT2i), tofogliflozin or ipragliflozin, achieve optimal glycemic variability, when used together with insulin glargine 300 U/mL (Glargine 300). Thirty patients with type 2 diabetes were randomly allocated to 2 groups. For the first group: After admission, tofogliflozin 20 mg was(More)
  • 1